State Street’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

State Street’s Portfolio NBRV Stock Details NBRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,437	Closed	-$51K	–	4982
2021 Q4	$51K	Hold	3,437	–	–	﹤0.01%	4699
2021 Q3	$102K	Sell	3,437 -3,896	-53%	-$110K	﹤0.01%	4543
2021 Q2	$248K	Buy	7,333 +3,036	+71%	+$113K	﹤0.01%	4133
2021 Q1	$178K	Buy	4,297 +860	+25%	+$53.4K	﹤0.01%	3857
2020 Q4	$208K	Buy	3,437 +25	+0.7%	+$2.71K	﹤0.01%	3749
2020 Q3	$455K	Buy	3,412 +65	+2%	+$10.9K	﹤0.01%	3579
2020 Q2	$565K	Buy	3,347 +3,228	+2,713%	+$538K	﹤0.01%	3521
2020 Q1	$17K	Sell	119 -8	-6%	-$2.45K	﹤0.01%	3710
2019 Q4	$42K	Sell	127 -2	-2%	-$917	﹤0.01%	3732
2019 Q3	$65K	Buy	+129	New	+$72.8K	﹤0.01%	3702

Other funds holding NBRV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

VFA

Values First Advisors Gray, Tennessee $192M AUM 24.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street's NBRV Position: Q1 2022 in Review

State Street sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q1 2022, closing a stake of 3,437 shares — an estimated $51K sold.

State Street first reported a position in NBRV in Q3 2019 and held it in 10 quarters. The position peaked at $565K in Q2 2020. 29 funds tracked by Wall St. Rank hold NBRV as of Q1 2022.

State Street reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q1 2022 after selling out during the quarter.
State Street sold 3,437 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q1 2022, an estimated $51K.
State Street first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2019 and held it in 10 quarters.
State Street's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $565K in Q2 2020.
29 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q1 2022.

Based on State Street's 13F filing for Q1 2022, filed 16 May 2022.